-
Uncategorized2 months ago
Agenus cancer cocktail records 0% response rate, missing midstage goal
Agenus cancer cocktail records 0% response rate, missing midstage goal
-
Uncategorized2 months ago
Novo’s late-stage sickle cell win piles pressure on competitors
Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating “separation amongst PK class candidates,” Truist analysts said...
-
Uncategorized2 months ago
STAT+: Finally cracking KRAS as a druggable target
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hiya. Today, we see a...
-
Uncategorized2 months ago
Lilly to buy Kelonia for $3.25B upfront, underlining its in vivo CAR-T strategy
Eli Lilly is going big on in vivo CAR-T therapy. The company said Monday that it would buy Kelonia Therapeutics, which has a Phase 1 program...
-
Uncategorized2 months ago
AACR: Endeavoring to go global, Zai Lab offers reality check on China’s biotech ascent
Since its 2014 founding, Zai Lab has built its business by licensing drugs from Big Pharma. But in the last three years, the company has sought...
-
Uncategorized2 months agoSTAT+: Pharmalittle: We’re reading about Trump boosting psychedelic treatment, the future for weight-loss drugs, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and rewarding, because that oh-so-familiar routine of meetings, online calls,...
-
Uncategorized2 months agoDecoding Resistance to Targeted Therapy via New Cancer Models
ATCC and the Broad Institute report the development of engineered isogenic cancer models designed to replicate resistance to targeted therapies, beginning with osimertinib, the latest-generation epidermal...
-
Uncategorized2 months ago
FDA Policy Tracker 2026: Psychedelics get a boost
A year of significant policy change at the FDA brought momentum and scrutiny into the new year. As 2026 gets underway, biopharma companies are responding to...
-
Uncategorized2 months ago
Odyssey tests IPO waters anew after quitting quest last year
Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.
-
Uncategorized2 months agoLilly publishes data confirming Foundayo’s safety profile
Eli Lilly has shared positive topline results from the Phase III ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron), compared to insulin glargine in...
